Neoadjuvant therapy in microsatellite-stable colorectal carcinoma induces concomitant loss of MSH6 and Ki-67 expression.
暂无分享,去创建一个
[1] S. Thibodeau,et al. Heterogenous MSH6 Loss Is a Result of Microsatellite Instability Within MSH6 and Occurs in Sporadic and Hereditary Colorectal and Endometrial Carcinomas , 2015, The American journal of surgical pathology.
[2] P. Saetrom,et al. Cell cycle regulation of human DNA repair and chromatin remodeling genes. , 2015, DNA repair.
[3] N. Petrelli,et al. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. , 2015, Clinical colorectal cancer.
[4] Y. Niv,et al. How reliable is immunohistochemical staining for DNA mismatch repair proteins performed after neoadjuvant chemoradiation? , 2014, Human pathology.
[5] A. Bojesen,et al. Heterogenous mismatch-repair status in colorectal cancer , 2014, Diagnostic Pathology.
[6] R. Pai,et al. Lynch syndrome-associated colorectal carcinoma: frequent involvement of the left colon and rectum and late-onset presentation supports a universal screening approach. , 2013, Human pathology.
[7] M. Ladanyi,et al. Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency , 2013, Modern Pathology.
[8] J. Weitzel,et al. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] S. Syngal,et al. Screening patients with colorectal cancer for Lynch syndrome: what are we waiting for? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] A. Krasinskas,et al. Challenging cases encountered in colorectal cancer screening for Lynch syndrome reveal novel findings: nucleolar MSH6 staining and impact of prior chemoradiation therapy. , 2011, Human pathology.
[11] J. Baranda,et al. Capecitabine versus 5-fluorouracil in colorectal cancer: where are we now? , 2011 .
[12] R. Yantiss,et al. Neoadjuvant Therapy Induces Loss of MSH6 Expression in Colorectal Carcinoma , 2010, The American journal of surgical pathology.
[13] K. Gravdal,et al. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis , 2009, British Journal of Cancer.
[14] H T Lynch,et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications , 2009, Clinical genetics.
[15] Robin L. Jones,et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer , 2009, Breast Cancer Research and Treatment.
[16] M. Ligtenberg,et al. Interpretation of Immunohistochemistry for Mismatch Repair Proteins is Only Reliable in a Specialized Setting , 2008, The American journal of surgical pathology.
[17] D. Chang,et al. The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch Syndrome: from bench to bedside , 2007, Familial Cancer.
[18] D. Klimstra,et al. The utility of immunohistochemical detection of DNA mismatch repair gene proteins , 2004, Virchows Archiv.
[19] B. Leggett,et al. Proliferation, apoptosis, and survival in high-level microsatellite instability sporadic colorectal cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] M. Biondi,et al. Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] T. Kunkel,et al. Functional Interaction of Proliferating Cell Nuclear Antigen with MSH2-MSH6 and MSH2-MSH3 Complexes* , 2000, The Journal of Biological Chemistry.
[22] G. Marsischky,et al. Redundancy of Saccharomyces cerevisiae MSH3 and MSH6 in MSH2-dependent mismatch repair. , 1996, Genes & development.